🔗 Permalink

Inventor profile of:

Bent Højgaard

City:

Allerod

Country:

Denmark

Published Applications:

Last publication date:

2023-03-23

Top Assignees for applications by Bent Højgaard

The entities that hold a legal rights for patent applications filed by inventor Højgaard Bent:

Solural Pharma ApS 4 Ballerup, Denmark
Saniona A/S 4 Ballerup, Denmark
Saniona A/S 2 Glostrup, Denmark
Ascelia Pharma AB 2 Malmö, Sweden
Novo Nordisk A/S 2 Bagsvaerd, Denmark
Oncoral Pharma ApS 1 Copenhagen, Denmark
Conrig Pharma ApS 1 Copenhagen N, Denmark
Contera Pharma A/S 1 Horsholm, Denmark
Oncoral Pharma ApS 1 Kgs. Lyngby, Denmark
LifeCycle Pharma A/S 1 Horsholm, Denmark
Oncoral Pharma ApS 1 Kongens Lyngby, Denmark
ONCORAL PHARMA APS 1 Lyngby, Denmark

Recent patent applications by Højgaard Bent

Bent Højgaard from Allerod, DK has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2023-03-23

US20230092397A1

Human necessities

Tesofensine and beta blocker combination formulations

#2 | 2022-11-10

US20220354799A1

Human necessities

Solid oral dosage form of irinotecan for the treatment of cancer

#3 | 2022-08-18

US20220257802A1

Human necessities

COMPRESSED SOLID COMPOSITION FOR MRI

#4 | 2021-01-28

US20210023050A1

Human necessities

Tesofensine and beta blocker combination formulations

#5 | 2020-12-10

US20200384129A1

Human necessities

Compressed solid composition for MRI

#6 | 2020-07-23

US20200230083A1

Human necessities

Composition comprising suplatast tosilate

#7 | 2020-04-30

US20200129478A1

Human necessities

Tesofensine and beta blocker combination formulations

#8 | 2019-09-26

US20190290587A1

Human necessities

Pulsatile drug delivery system for treating morning akinesia

#9 | 2018-12-27

US20180369153A1

Human necessities

Solid oral dosage form of irinotecan for the treatment of cancer

#10 | 2018-12-20

US20180360804A1

Human necessities

Tesofensine and beta blocker combination formulations

#11 | 2018-03-15

US20180071250A1

Human necessities

Tesofensine, beta blocker combination formulation

#12 | 2017-05-04

US20170119674A1

Human necessities

Solid oral dosage form of lipophilic compounds

#13 | 2016-11-17

US20160331692A1

Human necessities

Solid oral dosage form of irinotecan for the treatment of cancer

#14 | 2016-09-29

US20160279067A1

Human necessities

Tesofensine and beta blocker combination formulations

#15 | 2015-11-19

US20150328233A1

Human necessities

Solid oral dosage form of testosterone derivative

#16 | 2014-06-26

US20140179655A1

Human necessities

SOLID ORAL DOSAGE FORM OF TESTOSTERONE DERIVATIVE

#17 | 2011-12-01

US20110294852A1

Human necessities

Pharmaceutical Formulation Comprising Metformin and Repaglinide

#18 | 2011-10-06

US20110244031A1

Human necessities

POROUS TABLETS AS CARRIERS FOR LIQUID FORMULATIONS

#19 | 2010-02-04

US20100029721A1

Human necessities

Pharmaceutical Formulation Comprising Metformin and Repaglinide

InventorID:

816052 ⎘